The ha(r)sh-drug interactions in rheumatology

Luke Daniel Williamson¹, Peter Wong^{1

2}, Nicholas Manolios^{1

3}

Affiliations

¹ Department of Rheumatology, Westmead Hospital, Westmead, NSW, Australia.
² The University of New South Wales Rural Clinical School, Coffs Harbour, NSW, Australia.
³ The University of Sydney, Sydney, NSW, Australia.

Luke Daniel Williamson et al. Int J Rheum Dis. 2020 Sep.

. 2020 Sep;23(9):1258-1260.

doi: 10.1111/1756-185X.13939. Epub 2020 Aug 17.

Luke Daniel Williamson¹, Peter Wong^{1

2}, Nicholas Manolios^{1

3}

¹ Department of Rheumatology, Westmead Hospital, Westmead, NSW, Australia.
² The University of New South Wales Rural Clinical School, Coffs Harbour, NSW, Australia.
³ The University of Sydney, Sydney, NSW, Australia.

No abstract available

References

1. Narcotic Drugs Legislation Amendment Act. 2016 (Cth) s. 8D (Austl.). pp., Federal Register of Legislation. Retrieved from https://www.legislation.gov.au/Details/C2016A00012
1. Lynch ME, Campbell F. Cannabinoids for treatment of chronic non‐cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol. 2011;72(5):735‐744.
1. Fitzcharles M‐A, Baerwald C, Ablin J, Häuser W. Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis). Der Schmerz. 2016;30(1):47‐61.
1. Leung L. Cannabis and its derivatives: review of medical use. J Am Board Family Med. 2011;24(4):452‐462.
1. Sarzi‐Puttini P, Batticciotto A, Atzeni F, et al. Medical cannabis and cannabinoids in rheumatology: where are we now? Exp Rev Clin Immunol. 2019;15(10):1019‐1032.